STAAR Surgical Company (NASDAQ:STAA), trading on NASDAQ under the symbol STAA, specializes in phakic intraocular lenses (IOLs) with its EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction. The company is based in Lake Forest, California, and is known for its commitment to transparency with investors. STAAR competes in the medical device industry, focusing on innovative vision correction solutions.

On October 29, 2025, STAA reported earnings per share (EPS) of $0.17, slightly below the estimated $0.18. Despite this, the company generated revenue of $94.7 million, surpassing the estimated $89.4 million. This revenue performance reflects STAAR's strong sales, as highlighted in their preliminary net sales results for the third quarter of 2025.

TThe price-to-sales ratio of about 6 suggests that investors are willing to pay $6 for every dollar of sales, showing confidence in the company's revenue potential. The enterprise value to sales ratio is approximately 5.43, reflecting STAAR's valuation relative to its revenue. However, the enterprise value to operating cash flow ratio is around -42.74, indicating difficulties in generating positive cash flow from operations. Despite these challenges, STAA maintains a low debt-to-equity ratio of about 0.12, suggesting a relatively low level of debt compared to its equity.

Additionally, STAAR's current ratio is approximately 4.94, indicating strong liquidity and the company's ability to cover its short-term liabilities. This strong liquidity position provides a buffer for the company as it continues to focus on its core business of vision correction solutions.